Every material Form 8-K Theriva Biologics, Inc. has filed with the SEC since August 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On October 30, 2026, Theriva Biologics sold its SYN-004 (ribaxamase) and related SYN-006 antibiotic-degrading enzyme assets to Biossil Labs Inc., with the closing on the same day. Theriva received a $350,000 upfront payment and is eligible for regulatory and sales milestones and royalties, subject to a $250 million royalty cap, while Biossil takes over development and commercialization. Future payments are not assured, and Theriva must share part of its proceeds with PREV ABR LLC under an amended agreement.
Closing occurred October 30, 2026, and Theriva received a non-refundable $350,000 upfront payment
Theriva is eligible for up to $3 million in regulatory milestones, up to $88 million in sales milestones, and low-single-digit royalties capped at $250 million
Theriva paid PREV ABR LLC $140,000 at closing and will owe PREV 50% of milestones, 33 1/3% of royalties and 50% of other consideration, subject to a $13.0 million cap
Theriva Biologics reported a second-quarter 2026 net loss of $3.2 million, or $0.07 per share, compared with $13.1 million, or $1.93 per share, a year earlier. The company reported no license revenue in the quarter, and the drop in losses came mainly from lower general and administrative expenses. Cash and cash equivalents were $11.3 million at June 30, 2026, and the company said that cash runway extends into Q1 2027.
Q2 2026 net loss was $3.2 million, versus $13.1 million in Q2 2025; loss per share was $0.07, versus $1.93
General and administrative expenses fell 82% to $2.0 million, mainly because of a $9.2 million contingent consideration charge in the prior-year quarter
Research and development expenses fell 35% to $1.3 million
Cash and cash equivalents were $11.3 million at June 30, 2026, down $1.7 million from December 31, 2025, with runway into Q1 2027
Theriva Biologics said it dosed the first patient in VIRAGE2, a small Phase 2a proof-of-concept study of more frequent repeated dosing of VCN-01 in first-line metastatic pancreatic cancer patients. The study will enroll 6 evaluable patients at a single site in Spain, with enrollment expected to finish in H2 2026 and initial data expected by Q3 2027. The filing reports no revenue, earnings or financial results, and the study is not formally powered to assess clinical efficacy.
First patient dosed in VIRAGE2, announced August 6, 2026
Study planned for 6 evaluable patients at a single site in Spain
Enrollment expected to be completed in H2 2026; initial pharmacodynamic and safety data expected by Q3 2027
Results are intended to inform the VCN-01 dosing regimen for a possible future Phase 3 trial
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Theriva Biologics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →